Biography
Kayleigh joined Keele University as a Research Associate in Epidemiology and Biostatistics in 2020. Kayleigh previously worked as a Research Associate following her PhD in Medicine (2014) and BSc in Pharmacology (2010) at The University of Manchester.
Kayleigh currently works on a study funded by the Nuffield Foundation titled “The impact of musculoskeletal conditions on outcomes of other illnesses: a linked electronic health record study”.
Research and scholarship
Kayleigh’s expertise and research interests include analysing complex, longitudinal, real-world data and translating those findings into practical information for patients, healthcare professionals and the public.
Selected Publications
-
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. Br J Dermatol. link> doi> full text>2022.
-
P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study. Rheumatology, vol. 61(Supplement_1). doi> full text>2022.
-
Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). full text>
-
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol, e636-e640, vol. 35(10). link> doi> full text>2021.
- 2021.
Full Publications Listshow
Journal Articles
-
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. Br J Dermatol. link> doi> full text>2022.
-
P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study. Rheumatology, vol. 61(Supplement_1). doi> full text>2022.
-
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol, e636-e640, vol. 35(10). link> doi> full text>2021.
-
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, e496-e498, vol. 35(8). doi> link> full text>2021.
- 2021.
-
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol, 80-90, vol. 185(1). link> doi> full text>2021.
- 2020.
-
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol, 66-73, vol. 157(1). link> doi> full text>2021.
- 2020.
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol, 60-71, vol. 147(1). link> doi> full text>2021.
- 2020.
-
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 404-406, vol. 183(2). link> doi> link> full text>2020.
-
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol, 769-778, vol. 34(4). link> doi> full text>2020.
-
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 294-302, vol. 183(2). link> doi> link> full text>2020.
- 2020.
-
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 400-409, vol. 13(2). link> doi> link> full text>2020.
- 2019.
-
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 1265-1271, vol. 181(6). link> doi> link> full text>2019.
-
Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. Br J Dermatol, 894-901, vol. 180(4). link> doi> full text>2019.
-
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 256-264, vol. 181(2). link> doi> link> full text>2019.
-
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2120-2130, vol. 143(6). link> doi> link> full text>2018.
-
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 1069-1076, vol. 180(5). link> doi> link> full text>2018.
-
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol, 329-337, vol. 180(2). link> doi> full text>2019.
- 2018.
- 2018.
-
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 581-588, vol. 154(5). link> doi> link> full text>2018.
-
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol, 775-784, vol. 138(4). link> doi> full text>2018.
- 2018.
- 2018.
-
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 785-794, vol. 138(4). link> doi> link> full text>2017.
- 2017.
Other
-
Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). full text>
- 2021.
-
Factors associated with hospitalization due to COVID-19 in patients with psoriasis: insights from a global registry. BRITISH JOURNAL OF DERMATOLOGY (p. 200, vol. 183). link>2020.
-
Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 467, vol. 27). Journal of the European Academy of Dermatology and Venereology. link> doi> link> full text>2019.
-
Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 503, vol. 28). link>2019.
-
Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration. BRITISH JOURNAL OF DERMATOLOGY (p. 47, vol. 181). link>2019.
- 2019.
-
The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis. BRITISH JOURNAL OF DERMATOLOGY (p. 60, vol. 181). link>2019.
-
Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis. JOURNAL OF INVESTIGATIVE DERMATOLOGY (p. S39, vol. 139). link>2019.
-
A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 49, vol. 27). link>2018.
-
A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 16-17, vol. 27). link>2018.
-
Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 408, vol. 27). link>2018.
-
The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 17, vol. 27). link>2018.
- 2018.
- 2018.
-
THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. ACTA DERMATO-VENEREOLOGICA (p. 33, vol. 98). link>2018.
-
A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (p. E273, vol. 177). link>2017.
-
Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (pp. E272-E273, vol. 177). link>2017.
-
Completeness of Reporting of Overnight Hospitalisations to a Psoriasis Pharmacovigilance Register and the National Health Service Wales Informatics Service. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 564-565, vol. 26). link>2017.
-
Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (pp. 11-12, vol. 177). link>2017.
- 2016.
-
Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 438-439, vol. 25). link>2016.
- 2014.
Collaborations and grants awards
- Sep 2020 - Translation@Manchester Informatics Training Scheme, Wellcome Trust
- May 2019 - Albert M. Kligman Travel Fellowship, Society for Investigative Dermatology
- June 2018 - Best Oral Presentation, British Dermatology Nursing Group Annual Conference
- Jan 2018 - PhD Studentship, The Psoriasis Association (£84,000; 40% award as supervisor)
- Sep 2010 – PhD Studentship, Arthritis Research UK (Margaret Coupe Endowment)
School of Medicine
David Weatherall building
University Road
Keele University
Staffordshire
ST5 5BG
Tel: +44 (0) 1782 733937
Email: medicine.reception@keele.ac.uk
Admissions enquiries: enquiries@keele.ac.uk